Company: GlaxoSmithKline (GSK)
Posted by NucalaVet_GSK · March 22, 2026
Tags: territory, general
I've been in GSK respiratory for four years and the Nucala vs Fasenra battle is the most sustained competitive dynamic I've ever seen.
Both drugs are good.
Physicians who've had success with one are loyal to it.
The differentiation is real at the margins — dosing intervals, administration site, patient populations — but most severe asthma reps know we're competing for the undecided minority.
What I've noticed recently is that Fasenra is making inroads with pulmonologists while we're holding better with allergists.
Whether that's intentional targeting by AstraZeneca or just rep relationships, I can't say.
But it's a pattern worth noting.
40 upvotes · 0 comments